Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating critical facts inside TransMedics’ filings can feel like performing surgery without imaging. FDA approvals, clinical-trial endpoints, and the economics of single-use perfusion sets are scattered across hundreds of pages, while executive stock moves appear moments before major organ-care milestones. That complexity makes TransMedics SEC filings explained simply an urgent need for analysts and clinicians alike.
Stock Titan solves the puzzle with AI that dissects every submission the instant it hits EDGAR. Whether you need a TransMedics annual report 10-K simplified summary or a flagged line-item from the latest TransMedics quarterly earnings report 10-Q filing, our platform translates technical language into plain English. Real-time alerts surface TransMedics Form 4 insider transactions real-time, while concise notes decode TransMedics 8-K material events explained. Key features:
- AI-powered highlights of clinical data, R&D spend, and PMA supplements
- Instant access to TransMedics insider trading Form 4 transactions and option grants
- Side-by-side TransMedics earnings report filing analysis for trend spotting
- Clear pointers to TransMedics proxy statement executive compensation details
Use these insights to monitor transplant-volume targets, assess reimbursement risks, or track TransMedics executive stock transactions Form 4 before material disclosures. From understanding TransMedics SEC documents with AI to exporting data for valuation models, Stock Titan keeps surgeons, investors, and industry observers a step ahead—no medical degree required.
TransMedics Group (TMDX) reported strong third-quarter results. Total revenue rose to $143.8 million, up from $108.8 million a year ago, with net income of $24.3 million versus $4.2 million last year. Gross profit reached $84.6 million, reflecting higher product and service activity across the Organ Care System (OCS) platform.
Growth was concentrated in the United States, where OCS transplant revenue totaled $139.0 million, led by liver at $107.9 million and heart at $27.4 million. Diluted EPS was $0.66 (basic $0.71). Year‑to‑date, revenue was $444.7 million with $84.9 million of net income and $158.3 million in cash from operations.
The balance sheet strengthened with $466.2 million in cash and $355.2 million in stockholders’ equity. The company reported $452.1 million net carrying value of its 1.50% convertible senior notes due 2028 and $54.6 million in long‑term bank debt. As of October 17, 2025, 34,174,325 common shares were outstanding.
TransMedics Group, Inc. (TMDX) furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company specifies the information is being furnished, not filed, meaning it is not subject to Section 18 liability and will only be incorporated into other filings if expressly referenced. The common stock trades on the Nasdaq Global Market under the symbol TMDX.
TransMedics Group, Inc. filed a Form 8-K disclosing a material event: the company considers certain Acquisitions to be a series of related transactions to acquire a fleet of aircraft for use in its National OCS Program. The filing identifies this as a material event and is signed by Gerardo Hernandez, Chief Financial Officer and Treasurer on
Waleed H. Hassanein, President & CEO and director of TransMedics Group (TMDX), reported both purchases of company stock and a large disposition on a Form 4. The filing lists purchases on 08/06/2025 of 8,400 shares at a weighted average price of $118.68 and on 08/07/2025 of 6,617 shares at $116.08 and 1,858 shares at $116.85. Those purchases, held indirectly by the Waleed H. Hassanein Revocable Trust, increased reported beneficial ownership to 486,234 shares. The form also records a disposition of 121,424 shares but does not include a transaction date or price for that disposition. Footnotes state each purchase price is a weighted average across specified trade ranges and that the reporting person will provide per-trade details on request.
Form 4 summary: Reporting person Edward M. Basile (Director) filed a Form 4 for TransMedics Group, Inc. (TMDX) reporting transactions dated 08/04/2025.
Key reported items
- Non-derivative rows list 4,143 shares associated with a transaction code M and a quoted price of $0.70.
- A contemporaneous non-derivative row lists 4,143 shares with transaction code S and a price of $125.51.
- Post-transaction beneficial ownership figures shown: 7,009 shares and 2,866 shares (as reported).
- Derivative disclosure: a stock option with conversion/exercise price $0.70, underlying 4,143 common shares, exercisable 02/16/2026, and 4,142 derivative securities reported as beneficially owned following the transaction.
- Explanations state the option is fully vested and was adjusted on a 3.5-for-1 basis in connection with a pre-IPO conversion.
Filing: Signed by Attorney-in-Fact Gerardo Hernandez on 08/05/2025.
FAQ
What is the current stock price of Transmedics Group (TMDX)?
What is the market cap of Transmedics Group (TMDX)?
